Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
This article was originally published in The Pink Sheet Daily
Executive Summary
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.